Literature DB >> 18335518

Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model.

Igor Branchi1, Ivana D'Andrea, Monica Armida, Tommaso Cassano, Antonella Pèzzola, Rosa Luisa Potenza, Maria Grazia Morgese, Patrizia Popoli, Enrico Alleva.   

Abstract

To investigate the psychiatric symptoms accompanying the early phases of Parkinson's disease (PD), we injected adult rats with 10.5 microg 6-hydroxydopamine (6-OHDA) bilaterally into the dorsal striatum. The resulting neurodegeneration led, 12 weeks after injection, to a mild (36%) reduction of striatal dopamine. We tested the behavioral response of sham and 6-OHDA-lesioned animals at different time points after injection to evaluate the onset and progression of behavioral abnormalities. The results showed that such a mild reduction of dopamine levels was associated with a decrease in anxiety-like behavior, an increase in "depression"-like behavior, and a marked change in social behavior. Learning and memory abilities were not affected. Overall, the PD rat model used here displays behavioral alterations having face validity with psychiatric symptoms of the pathology and thus appears to be a valuable tool for investigating the neural bases of the early phases of PD. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335518     DOI: 10.1002/jnr.21642

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  28 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.

Authors:  Karen L Eskow Jaunarajs; Kristin B Dupre; Corinne Y Ostock; Thomas Button; Terrence Deak; Christopher Bishop
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

Review 4.  Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.

Authors:  Mohamed El-Gamal; Mohamed Salama; Lyndsey E Collins-Praino; Irina Baetu; Ahmed M Fathalla; Amira M Soliman; Wael Mohamed; Ahmed A Moustafa
Journal:  Neurotox Res       Date:  2021-03-25       Impact factor: 3.911

Review 5.  Endocannabinoid system in neurodegenerative disorders.

Authors:  Balapal S Basavarajappa; Madhu Shivakumar; Vikram Joshi; Shivakumar Subbanna
Journal:  J Neurochem       Date:  2017-07-05       Impact factor: 5.372

Review 6.  A guide to neurotoxic animal models of Parkinson's disease.

Authors:  Kim Tieu
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

7.  6-hydroxydopamine lesions in the rat neostriatum impair sequential learning in a serial reaction time task.

Authors:  Moritz Thede Eckart; Moriah Christina Huelse-Matia; Rebecca S McDonald; Rainer K -W Schwarting
Journal:  Neurotox Res       Date:  2010-04       Impact factor: 3.911

8.  Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion.

Authors:  Tommaso Cassano; Silvana Gaetani; Maria Grazia Morgese; Teresa Macheda; Leonardo Laconca; Pasqua Dipasquale; Juan Taltavull; Toni S Shippenberg; Vincenzo Cuomo; Gabriella Gobbi
Journal:  Neurochem Res       Date:  2009-02-20       Impact factor: 3.996

9.  Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Authors:  Melissa M Conti; Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Rich Dell'isola; Aaron C Katzman; Christopher Bishop
Journal:  Neuropharmacology       Date:  2013-09-22       Impact factor: 5.250

10.  Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

Authors:  Marta G Vucković; Ruth I Wood; Daniel P Holschneider; Avery Abernathy; Daniel M Togasaki; Alexandra Smith; Giselle M Petzinger; Michael W Jakowec
Journal:  Neurobiol Dis       Date:  2008-08-05       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.